Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
315 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Malignant Pleural Mesothelioma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Mesothelioma - Pipeline Review, H2 2016, provides an overview of the Malignant Pleural Mesothelioma (Oncology) pipeline landscape. Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Mesothelioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Malignant Pleural Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 2 molecules, respectively.Malignant Pleural Mesothelioma. Malignant Pleural Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma (Oncology). - The pipeline guide reviews pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Malignant Pleural Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Malignant Pleural Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Mesothelioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Malignant Pleural Mesothelioma Overview 8 Therapeutics Development 9 Pipeline Products for Malignant Pleural Mesothelioma - Overview 9 Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 10 Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 11 Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 13 Malignant Pleural Mesothelioma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Malignant Pleural Mesothelioma - Products under Development by Companies 17 Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 20 Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 21 Advantagene, Inc. 21 Amphera BV 22 AnGes MG, Inc. 23 ArQule, Inc. 24 Bayer AG 25 Biogen Inc 26 Bionomics Limited 27 Biotecnol Limited 28 Boehringer Ingelheim GmbH 29 Boston Biomedical, Inc. 30 Bristol-Myers Squibb Company 31 CanBas Co., Ltd. 32 Concordia International Corp 33 Eli Lilly and Company 34 EnGeneIC Ltd 35 F. Hoffmann-La Roche Ltd. 36 Genelux Corporation 37 GlaxoSmithKline Plc 38 Juno Therapeutics Inc. 39 MedImmune LLC 40 Merck & Co., Inc. 41 Millennium Pharmaceuticals Inc 42 MolMed S.p.A. 43 Morphotek, Inc. 44 Novartis AG 45 Ono Pharmaceutical Co., Ltd. 46 Oxford BioMedica Plc 47 Pharma Mar, S.A. 48 Polaris Pharmaceuticals, Inc. 49 Sellas Inc 50 Targovax ASA 51 VasGene Therapeutics, Inc. 52 Verastem, Inc. 53 Virttu Biologics Limited 54 Vyriad Inc 55 Malignant Pleural Mesothelioma - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Combination Products 57 Assessment by Target 58 Assessment by Mechanism of Action 61 Assessment by Route of Administration 64 Assessment by Molecule Type 66 Drug Profiles 68 alisertib - Drug Profile 68 amatuximab - Drug Profile 74 anetumab ravtansine - Drug Profile 76 bevacizumab - Drug Profile 79 BG-00001 - Drug Profile 88 BMS-986148 - Drug Profile 89 BNC-105 - Drug Profile 90 CBP-501 - Drug Profile 95 Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 97 Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile 98 Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile 99 CSG-MESO - Drug Profile 100 defactinib hydrochloride - Drug Profile 101 durvalumab - Drug Profile 108 durvalumab + tremelimumab - Drug Profile 119 galinpepimut-S - Drug Profile 123 ganetespib - Drug Profile 126 GEN-0101 - Drug Profile 138 Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 140 Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 141 GLONC-1 - Drug Profile 142 GSK-2256098 - Drug Profile 146 HSV-1716 - Drug Profile 148 iCasp9M28z - Drug Profile 151 JTCR-016 - Drug Profile 152 LY-3023414 - Drug Profile 154 MesoCancerVac - Drug Profile 156 MesoCART - Drug Profile 157 Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 158 MTG-201 - Drug Profile 160 napabucasin - Drug Profile 162 NGR-hTNF - Drug Profile 169 nintedanib - Drug Profile 175 nivolumab - Drug Profile 184 Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile 218 Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile 219 ONCOS-102 - Drug Profile 220 OXB-301 - Drug Profile 223 pegargiminase - Drug Profile 226 pembrolizumab - Drug Profile 233 porfimer sodium - Drug Profile 266 rAd-IFN - Drug Profile 268 S-588210 - Drug Profile 270 Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 271 TargomiRs - Drug Profile 272 TB-535 - Drug Profile 274 tivantinib - Drug Profile 275 trabectedin - Drug Profile 280 Vas-01 - Drug Profile 287 VS-5584 - Drug Profile 289 Malignant Pleural Mesothelioma - Dormant Projects 292 Malignant Pleural Mesothelioma - Discontinued Products 293 Malignant Pleural Mesothelioma - Product Development Milestones 294 Featured News & Press Releases 294 Appendix 310 Methodology 310 Coverage 310 Secondary Research 310 Primary Research 310 Expert Panel Validation 310 Contact Us 310 Disclaimer 311
List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016 13 Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Comparative Analysis by Late Stage Development, H2 2016 18 Comparative Analysis by Clinical Stage Development, H2 2016 19 Comparative Analysis by Early Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2016 24 Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H2 2016 25 Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H2 2016 26 Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H2 2016 27 Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H2 2016 28 Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H2 2016 29 Malignant Pleural Mesothelioma - Pipeline by Biogen Inc, H2 2016 30 Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H2 2016 31 Malignant Pleural Mesothelioma - Pipeline by Biotecnol Limited, H2 2016 32 Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 33 Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2016 34 Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2016 35 Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2016 36 Malignant Pleural Mesothelioma - Pipeline by Concordia International Corp, H2 2016 37 Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H2 2016 38 Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2016 39 Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 40 Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H2 2016 41 Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2016 42 Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2016 43 Malignant Pleural Mesothelioma - Pipeline by MedImmune LLC, H2 2016 44 Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H2 2016 45 Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 46 Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H2 2016 47 Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H2 2016 48 Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H2 2016 49 Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 50 Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2016 51 Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2016 52 Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 53 Malignant Pleural Mesothelioma - Pipeline by Sellas Inc, H2 2016 54 Malignant Pleural Mesothelioma - Pipeline by Targovax ASA, H2 2016 55 Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2016 56 Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H2 2016 57 Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2016 58 Malignant Pleural Mesothelioma - Pipeline by Vyriad Inc, H2 2016 59 Assessment by Monotherapy Products, H2 2016 60 Assessment by Combination Products, H2 2016 61 Number of Products by Stage and Target, H2 2016 63 Number of Products by Stage and Mechanism of Action, H2 2016 66 Number of Products by Stage and Route of Administration, H2 2016 69 Number of Products by Stage and Molecule Type, H2 2016 71 Malignant Pleural Mesothelioma - Dormant Projects, H2 2016 296 Malignant Pleural Mesothelioma - Discontinued Products, H2 2016 297
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
